Evidence map›Paper›PMID 32289156›Full record

ArticleThe Journal of experimental medicine2020

ACKR4 restrains antitumor immunity by regulating CCL21.

Carly E Whyte, Maleika Osman, Ervin E Kara, Caitlin Abbott, Jade Foeng, Duncan R McKenzie, Kevin A Fenix, Yuka Harata-Lee, Kerrie L Foyle, Sarah T Boyle and 9 more

Expression of concernOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of experimental medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Tumour-retained activated CCR7Nature communications · 2024
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Physiology of chemokines in the cancer microenvironment.American journal of physiology. Cell physiology · 2023
    Review
  13. Hepatocellular Carcinoma Subtyping and Prognostic Model Construction Based on Chemokine-Related Genes.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2023
    Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Immune evasion in HPVProceedings of the National Academy of Sciences of the United States of America · 2021
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Carly E WhyteChemokine Biology Laboratory, Department of Molecular and Biomedical Science, School of Biological Sciences, The University of Adelaide, Adelaide, South Australia, Australia.
Maleika OsmanChemokine Biology Laboratory, Department of Molecular and Biomedical Science, School of Biological Sciences, The University of Adelaide, Adelaide, South Australia, Australia.
Ervin E KaraChemokine Biology Laboratory, Department of Molecular and Biomedical Science, School of Biological Sciences, The University of Adelaide, Adelaide, South Australia, Australia.
Caitlin AbbottChemokine Biology Laboratory, Department of Molecular and Biomedical Science, School of Biological Sciences, The University of Adelaide, Adelaide, South Australia, Australia.
Jade FoengChemokine Biology Laboratory, Department of Molecular and Biomedical Science, School of Biological Sciences, The University of Adelaide, Adelaide, South Australia, Australia.
Duncan R McKenzieChemokine Biology Laboratory, Department of Molecular and Biomedical Science, School of Biological Sciences, The University of Adelaide, Adelaide, South Australia, Australia.
Kevin A FenixChemokine Biology Laboratory, Department of Molecular and Biomedical Science, School of Biological Sciences, The University of Adelaide, Adelaide, South Australia, Australia.
Yuka Harata-LeeChemokine Biology Laboratory, Department of Molecular and Biomedical Science, School of Biological Sciences, The University of Adelaide, Adelaide, South Australia, Australia.
Kerrie L FoyleChemokine Biology Laboratory, Department of Molecular and Biomedical Science, School of Biological Sciences, The University of Adelaide, Adelaide, South Australia, Australia.
Sarah T BoyleCentre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, South Australia, Australia.
Marina KochetkovaCentre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, South Australia, Australia.
Amelia Roman AguileraImmunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Jiajie HouImmunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Xian-Yang LiImmunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Mark A ArmstrongBioinformatics Hub, School of Biological Sciences, The University of Adelaide, Adelaide, South Australia, Australia.
Stephen M PedersonBioinformatics Hub, School of Biological Sciences, The University of Adelaide, Adelaide, South Australia, Australia.
Iain ComerfordChemokine Biology Laboratory, Department of Molecular and Biomedical Science, School of Biological Sciences, The University of Adelaide, Adelaide, South Australia, Australia.
Mark J SmythImmunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Shaun R McCollChemokine Biology Laboratory, Department of Molecular and Biomedical Science, School of Biological Sciences, The University of Adelaide, Adelaide, South Australia, Australia.
The University of Adelaide · AUQIMR Berghofer Medical Research Institute · AUSouth Australia Pathology · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current immunotherapies involving CD8+ T cell responses show remarkable promise, but their efficacy in many solid tumors is limited, in part due to the low frequency of tumor-specific T cells in the tumor microenvironment (TME). Here, we identified a role for host atypical chemokine receptor 4 (ACKR4) in controlling intratumor T cell accumulation and activation. In the absence of ACKR4, an increase in intratumor CD8+ T cells inhibited tumor growth, and nonhematopoietic ACKR4 expression was critical. We show that ACKR4 inhibited CD103+ dendritic cell retention in tumors through regulation of the intratumor abundance of CCL21. In addition, preclinical studies indicate that ACKR4 and CCL21 are potential therapeutic targets to enhance responsiveness to immune checkpoint blockade or T cell costimulation.

Indexed as

ImmunityAnimalsAntigens, CDCD8-Positive T-LymphocytesCell ProliferationChemokine CCL21Dendritic CellsDisease Models, AnimalHumansImmune Checkpoint InhibitorsIntegrin alpha ChainsMice, Inbred C57BLNeoplasm MetastasisNeoplasmsReceptors, CCRStromal CellsAckr4 protein, mousealpha E integrinsAntigens, CDChemokine CCL21Immune Checkpoint InhibitorsIntegrin alpha ChainsReceptors, CCR

Identifiers

PMID32289156
PMCPMC7971131
OpenAlexW3015927665

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.